Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

Rhea-AI Summary

Labcorp (NYSE: LH) appointed John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors effective February 9, 2026.

Dr. Sampson is vice chancellor for health affairs and dean at University of Colorado Anschutz School of Medicine, a practicing neurosurgeon, National Academy of Medicine member, and will join the Quality and Compliance Committee.

Positive

• Board gains deep clinical and research expertise in oncology and neuroscience
• Appointee is a National Academy of Medicine member with ~300 peer-reviewed publications
• Adds operational health system leadership experience from Duke Health
• Appointment to Quality and Compliance Committee strengthens governance focus

Negative

• None.

BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.

Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He also has deep expertise in oncology, neuroscience, women's health and personalized medicine which aligns with Labcorp's strategic areas of focus.

"John is widely respected as a leader in academic medicine, clinical practice, health system strategy and research," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His expertise will help advance Labcorp's strategy across diagnostics and drug development and enhance the value we deliver to customers."

Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.

"Labcorp plays a critical role in advancing earlier diagnosis, personalized medicine and the development of new therapies," said Dr. Sampson. "I look forward to contributing my clinical and research experience to help further the company's mission of improving health and improving lives."

In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-appoints-john-h-sampson-md-phd-to-board-of-directors-302682096.html

SOURCE Labcorp Holdings Inc

FAQ

Who is John H. Sampson and why was he appointed to Labcorp's board (LH) on Feb 9, 2026?

He is a neurosurgeon and academic leader appointed to Labcorp's board to add clinical and research expertise. According to the company, his background in oncology, neuroscience and health system leadership aligns with Labcorp’s diagnostics and drug development strategy.

What role will Dr. John Sampson hold on Labcorp's board and which committee did he join?

Dr. Sampson will serve as a director and member of the Quality and Compliance Committee. According to the company, his appointment is effective February 9, 2026, to help advance quality, compliance and clinical strategy across Labcorp.

How does Dr. Sampson's background support Labcorp (LH) strategic priorities in diagnostics and drug development?

His clinical, research and health system leadership supports diagnostics and drug development initiatives. According to the company, his expertise in personalized medicine, oncology and neuroscience is directly relevant to Labcorp’s strategic focus areas.

What are Dr. Sampson's key qualifications noted by Labcorp in the Feb 9, 2026 announcement?

Key qualifications include being a practicing neurosurgeon, National Academy of Medicine member, and author of nearly 300 peer-reviewed publications. According to the company, he also held senior leadership roles at Duke and leads the CU Anschutz School of Medicine.

When did John H. Sampson officially join Labcorp's board (LH) and what is his current professional position?

He officially joined the board effective February 9, 2026 and serves as vice chancellor for health affairs and dean at CU Anschutz School of Medicine. According to the company, he will contribute clinical and research experience to the board.